$NOVO B (-1,56 %) - 40 shares as an initial purchase. Leave it and wait.
Novo Nordisk
Action
Action
ISIN: DK0062498333
Ticker: NOVO B
DK0062498333
NOVO B
Price
Discussion sur NOVO B
Postes
749
6H·
Hims & Hers Health - Highlights of the results in Q3 2025
- Revenue: USD 599.0 million (estimated USD 580.4 million) ✅ ; increase of +49 % compared to the previous year
- Earnings per share: $0.06 (forecast: $0.10) 🟥
- Subscribers: 2.47 million; +21 % compared to the previous year
- Monthly online revenue per average subscriber: USD 80; +19 % compared to the previous year
- Online revenue: USD 589.1 million; +50% compared to the previous year
- Wholesale sales: USD 9.9 million; +10% compared to the previous year
Guidance:
- Q4 revenue: USD 605m to USD 625m (estimated USD 629.7m)
- Q4 Adj. EBITDA: USD 55-65 million; margin 9-10%
- Sales in financial year 2025: USD 2.335 billion - USD 2.355 billion; margin 13%
- Adjusted EBITDA for the financial year 2025: USD 307 million - USD 317 million
- Outlook for the adjusted EBITDA margin in the financial year 2025: approx. 13%
Further key figures:
- Net income: USD 15.8 million; decrease of 79% compared to the previous year (previous year included tax benefit of USD 60.8 million)
- Adjusted EBITDA: USD 78.4 million (forecast: USD 51.1 million compared to the previous year); +53% compared to the previous year
- Gross profit margin: 74% (compared to 79% in the previous year)
- Free cash flow: USD 79.4 million; unchanged from the previous year
- Cash flow from operating activities: USD 148.7 million; +74% compared to the previous year
- Cash and cash equivalents: solid balance sheet maintained
CEO commentary - Andrew Dudum:
🔸 "We're building a platform that becomes more personalized and proactive as it grows and appeals to more and more people."
🔸 "We are launching new specialties, partnering with leading healthcare companies and making significant progress in building Hims & Hers into a global brand."
CFO comment - Yemi Okupe:
🔸 "We delivered another quarter of strong, profitable growth - sales up 49% and adjusted EBITDA up 53% year-on-year."
🔸 "We are confident that we will exceed the ambitious targets for 2030 that we set ourselves at the beginning of this year."
Strategic update:
🔸 Active discussions are ongoing with Novo Nordisk on offering Wegovy injections and future oral versions via the Hims & Hers platform (subject to agreement).
CEO Comment - Andrew Dudum:
The third quarter results are in and here are the key points:
We are growing quickly and efficiently. Sales have increased by 49 % compared to the previous year. Adjusted EBITDA has increased by 53%. We are increasingly confident that we can achieve and even exceed our 2030 targets of USD 6.5 billion in sales and USD 1.3 billion in adjusted EBITDA.
Growth is becoming increasingly diversified. Hims is recording annual growth of 40 %, not including the generic PRN business, from which we are withdrawing. Hers is targeting high double-digit to triple-digit growth and is expected to achieve sales of over USD 1 billion next year.
- The scale of our customer platform allows us to bring you the best offerings in healthcare. From advanced diagnostics to early-stage biotechnology. We are committed to bringing you the best products at affordable prices.
As we grow, we pass the savings on to the consumer. We started the year with approximately 400,000 square feet of vertically integrated manufacturing space and expect to end the year with over 1 million square feet. Consumers will benefit the most from our expansion. State-of-the-art infrastructure, FDA-registered production facilities and GreenList-certified suppliers for GLP-1 products mean real benefits for consumers.
New categories such as testosterone and menopause are expected to be growth drivers next year. Excellent initial signals and a good product-market fit. Now we are focusing on optimizing business processes.
The comprehensive laboratory tests are on schedule to be launched by the end of the year at a fraction of the cost of comparable sophisticated tests today. We are talking about hundreds, not thousands. Over time, we will continue to expand this laboratory infrastructure vertically to keep costs as low as possible.
Longevity will start next year. The plan is to integrate peptides, coenzymes, GLP/GIP, supplements and tracking capabilities. If celebrities have access to these cutting-edge precision therapies, we want you to benefit too. Our California facilities are working hard to develop core peptides.
International expansion is imminent. Canada will follow shortly and we are in intensive discussions with leading generic manufacturers to offer semaglutide as a generic in Canada and Brazil from 2026. We continue to invest in the UK and Germany and are exploring other international markets such as Australia and other Latin American and Asian countries.
Our goal has not changed: We want to help make the world feel great.
+ 1
1717
12 Commentaires
Was it not only recently that Novo Nordisk was parted from in a dispute?
•
44
•
16H·
Novo Nordisk vs Nike: A Valuation Comparison
If I had to choose today, I'd lean toward Novo Nordisk $NOVO B (-1,56 %)
for maximum upside potential, but the choice depends entirely on your risk tolerance and investment timeline. Let me break down why these two companies are in completely different phases and what each offers.
Financial Metrics Comparison: Novo Nordisk $NOVO B (-1,56 %) vs Nike $NKE (-0,81 %) .
The Valuation Divide
The most striking difference between these two stocks is their valuation positioning. Novo Nordisk is trading at a P/E ratio of 12.66x while Nike commands 32.25x—a 2.5x difference. Novo Nordisk's current price of $49.13 is significantly undervalued according to DCF analysis, with conservative estimates suggesting fair value at $77.40 (57% upside) and more bullish valuations reaching $163.92 (234% upside). In contrast, Nike at $62.89 is essentially fairly valued according to its DCF fair value of $62.84, making it not particularly attractive from a pure valuation standpoint.
Business Quality & Scale
Novo Nordisk is the larger business by revenue at $290.4 billion versus Nike's $51.4 billion. More importantly, Novo generates $101 billion in net income compared to Nike's modest $5.7 billion—an 18x difference in absolute profitability. Novo's operating margin of 44.2% is extraordinary, reflecting the high-margin nature of pharmaceutical products like Ozempic and Wegovy. Nike's 12.3% operating margin reveals the challenges facing the consumer discretionary business facing tariffs and competitive pressures.
Growth Prospects
Here's where the narratives diverge significantly. Novo Nordisk delivered 25.2% revenue growth in 2024, but management cut full-year 2025 guidance to 8-14% growth (down from 13-21%) due to intensifying competition from Eli Lilly's superior tirzepatide drugs and compounded semaglutide alternatives. Despite market share erosion, Wegovy sales still surged 67% in Q2 2025, showing the underlying market remains enormous.
Nike is in the early stages of a turnaround under new CEO Elliott Hill. While facing mid-single digit revenue declines in the near term, analysts see a potential recovery catalyst from the 2026 FIFA World Cup, which could generate an additional $1.3 billion in sales. Analysts also highlight improved product innovation with 26 new products coming in 2026 and optimized running shoe offerings.
The Risk-Reward Profile
Novo Nordisk risks: The GLP-1 market is being reshaped by superior competitors. Eli Lilly's tirzepatide is demonstrably more effective for weight loss than Novo's semaglutide, and Lilly is winning market share. Additionally, the proliferation of compounded (unregulated) versions threatens pricing power. However, the obesity care market is projected to reach $150 billion by the early 2030s, offering enormous runway even for second-place competitors.
Nike risks: The company faces $1 billion in tariff headwinds that it's managing through production shifts and modest price increases. Consumer discretionary spending is under pressure. However, Nike has 150+ years of brand heritage, and historically, turnarounds in apparel/footwear tend to create outsized returns once momentum shifts.
Income Considerations
Nike offers a 2.48% dividend yield versus Novo's 0.37%, which matters if you need income. However, Novo's lower payout reflects its growth stage in the obesity drug market.
My Assessment
For growth investors with 3+ year horizon: Novo Nordisk offers substantially better risk-reward. Even if fair value falls to the conservative $77.40 estimate, you're looking at 57% upside, and multiple expansion could drive it higher as competitive dynamics stabilize. The pharmaceutical giant will likely defend its market position despite Lilly's advantages.
For value plus recovery upside: Nike could work if you believe in Elliott Hill's turnaround thesis and want exposure to World Cup tailwinds. Analysts collectively see 31% upside to $82.54 over 12 months, though this assumes execution on the turnaround.
The Choice: Novo Nordisk is the obvious selection if you want better valuation, superior profitability, and significant upside. You're buying a temporary weakness in an enormously profitable franchise facing manageable competitive headwinds. Nike is the more uncertain turnaround story, though it offers slightly more downside protection given its valuation is fair rather than deeply discounted.
The key catalyst to watch for Novo is their Q3 2025 earnings on November 5th, where Medicare pricing negotiations for semaglutide could unlock new obesity coverage opportunities.
20H·
Monthly portfolio update - October
My portfolio showed a decline of -2.16% this month. I took advantage of dips in $HAUTO (-3,01 %) and $BNP (-1,22 %) to add to my positions. I’m invested in $CMCSA (-0,2 %) and have opened positions there because they are shifting their focus towards entertainment and streaming, which I believe is a big part of the future.
The best performers this month were:
Qualcomm $QCOM (-1,49 %)
CN Railway $CNR (-0,64 %)
CIBC $CM (-0,47 %)
Chevron $CVX (-0,25 %)
On the downside:
Höegh Autoliners $HAUTO (-3,01 %)
Novo Nordisk $NOVO B (-1,56 %)
UnitedHealth Group $UNH (-1,14 %)
Bitcoin $BTC (-1,77 %)
Ethereum $ETH (-1,79 %)
Since Novo Nordisk and UnitedHealth are my largest positions, their weak performance had a significant impact on my portfolio.
It was a cautious month with mixed results. I’m staying patient and ready for better opportunities ahead.
88
3 Commentaires
18H
Just checked your portfolio, it's far from diversified, no wonder your monthly performance was negative...
Looking forward to you diversifying and being green by year end 💹
Looking forward to you diversifying and being green by year end 💹
•
11
•
23H·
📈 Portfolio Update – Restructuring and New Positions
Hello getquin community,
In the past few days, I’ve restructured my portfolio, focusing on companies with strong fundamentals, active buyback programs, and long-term strategies aimed at sustainable growth.
Here’s a breakdown of my latest moves 👇
💊 Novo Nordisk $NOVO B (-1,56 %)
Following the recent market drop, I still see Novo Nordisk as an excellent company. Its restructuring plan focuses on cost reduction, revenue stability, and a lower debt level compared to 2024. The ongoing buyback program reinforces confidence in the company’s long-term outlook.
💳 PayPal $PYPL (-1,49 %)
I increased my position after a strong quarterly report and the announcement of new strategic partnerships. I expect substantial revenue growth in the coming years. The company maintains a very low debt level and has a solid buyback plan in place.
💉 Merck & Co. $MRK (+0,56 %)
I’ve also increased my stake here. Earnings are growing, margins remain strong, and cash flow is excellent. Merck continues to support shareholder value through its buyback program and disciplined financial management.
📶 Verizon $VZ (+0,75 %)
I added to my position despite the recent drop, which I see as unjustified given the solid quarterly results. The dividend yield is attractive and sustainable. Debt remains high relative to equity, but it’s steadily declining. The only downside is the continuous, even if small, issuance of new shares.
🎬 Comcast $CMCSA (-0,2 %)
I increased my holdings after the stock fell despite a quarterly report that was broadly in line with expectations. At current prices, Comcast remains a strong company with sustainable dividends, declining debt, solid cash flow, and an ongoing buyback program.
💻 TeamViewer $TMV (-2,75 %)
After the sharp correction, I consider the stock attractive at current levels. The company is investing in AI, has strong margins, and maintains a positive cash flow. Debt levels are high but decreasing, while profits have shown excellent growth this year.
🌞 Solaria Energía $SLR (-0,64 %)
Cash flow is currently negative due to heavy investments, but these are starting to bear fruit. The company targets a +60% increase in operating margin compared to 2024, with further growth expected into 2026.
Instead, what do you think about these companies?
14Positions
3,38 %
3 Commentaires
Painpal as your biggest position, pure masochism.
••
1J·
⚠️Breaking News ⚠️ Ozempic turns people into "zombies"
The bad news for $NOVO B (-1,56 %) will not stop - a zombie apocalypse of "biblical proportions" threatens
Ps. Sorry for my late Halloween post 😂
1818
11 Commentaires
But it's also a crazy new finding that losing weight too quickly leaves unpleasant marks on the entire body 😂
•
99
•
1J·
📊 My portfolio update October 2025
After a volatile September with +6,2% the stabilization continued in October. My portfolio rose to 40.233 € and increased by +2,80 % slightly weaker than the NASDAQ 100 (+6.95 %)but still solidly in the green. While the major indices were driven by big tech, my portfolio once again showed strength in niche and future themes. ⚙️
1. performance & comparison 🚀
There was a moderate recovery over the course of the month: while the markets initially fluctuated, momentum returned towards the end.
With +2,8 % my portfolio remained below the NASDAQ 100, but performed better than broader indices such as the FTSE All World (+4.45 %) and DAX (+4.11 %) stable.
Particularly positive: the continued consolidation following the tech rallies of the previous months.
2. my savings plans & allocation 💶
My focus remains clear: managing liquidity and making targeted use of opportunities.
Since October, my new savings plan has been running on the Euro Overnight Rate Swap ETF (€ 500 per month) - as a flexible, interest-bearing "cash parking space" with daily liquidity and currently over 3.9 % return p.a. This allows me to keep capital ready to invest in quality shares in the event of setbacks.
3rd top mover in October 🟢
The month was led by IREN $IREN (-5,17 %)
(+25,8 %)which once again benefited from the massive demand for computing power for AI. Also Snowflake $SNOW (-1,21 %)
(+22,8 %) also made strong gains as investors increasingly focused on data-driven platforms again. The VanEck Uranium & Nuclear Energy ETF (+18.5 %) $NUKL (-2,64 %) rose significantly, driven by the ongoing global reassessment of nuclear energy as a stable and low-carbon energy source. Geopolitical tensions and supply bottlenecks provided an additional boost. While American Lithium (+15.4 %) was supported by positive industry news. Also CrowdStrike $CRWD (-1,23 %)
(+14 %) also impressed with strong demand in the cybersecurity segment and Datadog $DDOG (-2,25 %)
(+12,2 %) benefited from robust cloud spending by large companies.
4th flop mover in October 🔴
On the losing side was Ferrari $RACE (+1,57 %)
(-17,1 %)which was burdened by profit-taking and a more cautious outlook after a strong summer quarter. Tomra Systems $TOM (-0,34 %)
(-15 %) corrected after weaker volume growth, while Rheinmetall $RHM (-2,76 %)
(-14,1 %) suffered from geopolitical uncertainty despite a high order situation. Also Novo Nordisk $NOVO B (-1,56 %)
(-6,8 %) also fell further as regulatory risks surrounding GLP-1 once again came into focus. BYD $1211 (-2,88 %)
(-5,9 %) was volatile, weighed down by price pressure in China, while even Berkshire Hathaway $BRK.B (-0,07 %)
(-2,7 %) closed slightly in the red.
5. conclusion 💡
October showed: Rotation instead of rally. Techs with real profitability are gaining momentum again, while overheated stocks are consolidating.
With the overnight ETF, I am deliberately building up a strategic "interest rate anchor" in order to remain flexible in the coming months.
My focus remains clear: Quality, liquidity and long-term scaling.
❓ Question for the community:
Which stock surprised you the most in October - positive or negative?
👇 Write it in the comments!
+ 1
2727
15 Commentaires
Thank you, very nice update. I am still a fan
•
33
•
1J·
On the road to financial freedom - October update 📊
October marks the end of one of the most turbulent months for my portfolio. My portfolio reached a new ATH and I had the highest absolute daily gain (approx. 50,000 euros) and the highest daily loss (also approx. 50,000 euros) within a few days.
Start: 1,116,452 euros
End: 1,152,698 euros
Deposit: 26,034 euros
Profit: + 10,212 euros (+0.89%)
Anyone who has ever looked at my portfolio will know that I am significantly overweighted in gold, or more precisely in gold mines. This quickly explains the reason for the volatility. 🎢
In the shadow of the gold price, mines have of course also risen disproportionately. With the slump in the gold price by 10% in places in just a few days, the good performance of the mines also came to an end. Some of the junior mines recorded price falls of over 50% in just one week (fortunately not mine).
While gold $4GLD (+0,11 %) still rose by +3.8% in October, the October performance of K92 Mining (my largest position) was $KNT (+0,2 %) (my largest position) was +5.5% and Equinox Gold $EQX (-1,28 %) was +0.8%. I assume that gold will continue to perform well, as none of the problems (geopolitical tensions, inflation, etc.) have been solved. For this reason, I have also taken another small position $SCZ (-4,18 %) (SantaCruz Silver Mining) in the portfolio. The crash offered a very good opportunity! 📈
Novo-Nordirsk performed less well this month $NOVO B (-1,56 %) with -15% and PayPal $PYPL (-1,49 %) with +3.9%. PayPal is particularly disappointing here, as the quarterly figures were excellent. This sent the share up almost 18% intraday. Unfortunately, it was subsequently sold off completely. But this confirms my belief that you just have to be patient with PayPal. The day of truth for Novo-Nordirsk will come next week... 📉
Otherwise, I received around 700 euros in dividends this month and realized around 3,000 euros in gains on Mercedes and Alibaba, among others. 💵
➡️🆓: On my way towards 4 million total assets, the target achievement rate is now 39.9%. 😊
Let's see how November turns out. As always, it remains exciting!
1616
26 Commentaires
1J
To everyone else who thinks that the promised land of financial freedom has been reached with a custody account volume of 1 million: That's a mistake - it just goes on in the hamster wheel of capital targets! 😁
•
2929
•2J·
Quartalszahlen 03.11.25-07.11.15
$BNTX (-0,86 %)
$ON (-1,69 %)
$HIMS (-5,23 %)
$PLTR (-7,94 %)
$O (-0,38 %)
$8058 (-3,99 %)
$7974 (+3,03 %)
$BP. (-0,08 %)
$BOSS (-3,23 %)
$SWK (-4,4 %)
$SPOT (+3,37 %)
$N1CL34
$UBER (-5,26 %)
$CPRI (+4,78 %)
$SHOP (-3,96 %)
$RACE (+1,57 %)
$HOG (-0,38 %)
$HTZ (-3,09 %)
$PFIZER
$UPST (-2,66 %)
$ANET (-2,74 %)
$PINS
$TEM (-4,21 %)
$AMD (-2,45 %)
$SMCI (-2,63 %)
$RIVN (-1,48 %)
$BYND (-6,87 %)
$KTOS (-4,08 %)
$CPNG (-2,12 %)
$BMW (-1,81 %)
$NOVO B (-1,56 %)
$FRE (-1,9 %)
$ORSTED (-3,61 %)
$AG1 (-5,1 %)
$EVT (-1,42 %)
$CCO (-2,63 %)
$DOCN (-2,44 %)
$LMND (-3,62 %)
$SONO (-1,01 %)
$MCD (+0,44 %)
$HOOD (-3,41 %)
$QCOM (-1,49 %)
$FTNT (-1,18 %)
$FSLY (-2,18 %)
$HUBS (-1,32 %)
$ELF (-1,66 %)
$ARM (-2,6 %)
$SNAP (-1,5 %)
$DASH (-1,25 %)
$APP (-0,75 %)
$AMC (-1,11 %)
$ZIP (-0,82 %)
$FIG (-3,09 %)
$LCID (-2,75 %)
$DUOL
$UN0 (+0,34 %)
$CBK (-1,4 %)
$DEZ (-2,97 %)
$ZAL (-3,29 %)
$HEN (+0,19 %)
$MAERSK A (-1,28 %)
$HEI (-1,86 %)
$CON (-1,34 %)
$AZN (-1,07 %)
$ALB (-3,79 %)
$MRNA (-0,28 %)
$QBTS (-3,43 %)
$WBD (-0,64 %)
$LI (-1,97 %)
$RHM (-2,76 %)
$DDOG (-2,25 %)
$RL (-0,52 %)
$OPEN (-3,74 %)
$ABNB (-0,93 %)
$PTON (-1,55 %)
$MP (-2,22 %)
$TTD (-1,43 %)
$STNE (-3,36 %)
$SQ (-1,9 %)
$GRND (-0,84 %)
$IREN (-5,17 %)
$AFRM (-2,21 %)
$CRISP (+0,03 %)
$RUN (-2,74 %)
$7011 (-1,32 %)
$DTG (-1,34 %)
$HAG (-3,57 %)
$DKNG (-2,9 %)
$LAC (-3,36 %)
$KKR (-0,61 %)
$PETR3 (-1,11 %)
$CEG
$WEED (-1,52 %)
77
Titres populaires
Meilleurs créateurs cette semaine
Données en temps réel par LSX · Données financières de FactSet